Famot (famotidine): Uses, Dosage & Side Effects

What it's for (Indications)

Famotidine is indicated for the treatment of active duodenal ulcer (DU) and benign gastric ulcer (GU), including risk reduction for DU recurrence.
It is also used for Zollinger-Ellison syndrome and the treatment and prevention of gastroesophageal reflux disease (GERD), encompassing symptomatic nonerosive GERD and erosive esophagitis due to GERD.
Furthermore, it is indicated for pathological hypersecretory conditions and in pediatric patients for peptic ulcer disease and GERD.

Dosage Information

Type	Guideline
Standard	Famotidine is administered orally, typically once daily, with or without meals. For post-meal symptoms, taking the dose prior to the meal may be beneficial. Dosage and duration are individualized based on clinical response and condition. Adults: Active Duodenal Ulcer (DU): 40 mg once daily or 20 mg twice daily. Active Gastric Ulcer (GU): 40 mg once daily. Symptomatic Nonerosive GERD: 20 mg twice daily. Erosive Esophagitis due to GERD: 20 mg twice daily or 40 mg twice daily. Pathological Hypersecretory Conditions: Initially 20 mg every 6 hours, adjusted to patient needs; maximum 160 mg every 6 hours. Risk Reduction of DU Recurrence: 20 mg once daily. Pediatrics: Peptic Ulcer Disease (1 year to less than 17 years): Starting dosage 0.5 mg/kg once daily or 0.25 mg/kg twice daily; may increase to 1 mg/kg once daily at bedtime or 0.5 mg/kg twice daily; maximum daily dose is 40 mg. GERD (Birth to less than 3 months): Starting dosage 0.5 mg/kg once daily; may increase to 1 mg/kg once daily. GERD (3 months to less than 1 year): Starting dosage 0.5 mg/kg twice daily; may increase to 1 mg/kg twice daily; maximum daily dose is 40 mg. GERD with or without esophagitis and ulcerations (1 year to less than 17 years): Dosing is generally similar to Peptic Ulcer Disease for this age group.

Type

Guideline

Standard

Famotidine is administered orally, typically once daily, with or without meals. For post-meal symptoms, taking the dose prior to the meal may be beneficial. Dosage and duration are individualized based on clinical response and condition. **Adults:** Active Duodenal Ulcer (DU): 40 mg once daily or 20 mg twice daily. Active Gastric Ulcer (GU): 40 mg once daily. Symptomatic Nonerosive GERD: 20 mg twice daily. Erosive Esophagitis due to GERD: 20 mg twice daily or 40 mg twice daily. Pathological Hypersecretory Conditions: Initially 20 mg every 6 hours, adjusted to patient needs; maximum 160 mg every 6 hours. Risk Reduction of DU Recurrence: 20 mg once daily. **Pediatrics:** Peptic Ulcer Disease (1 year to less than 17 years): Starting dosage 0.5 mg/kg once daily or 0.25 mg/kg twice daily; may increase to 1 mg/kg once daily at bedtime or 0.5 mg/kg twice daily; maximum daily dose is 40 mg. GERD (Birth to less than 3 months): Starting dosage 0.5 mg/kg once daily; may increase to 1 mg/kg once daily. GERD (3 months to less than 1 year): Starting dosage 0.5 mg/kg twice daily; may increase to 1 mg/kg twice daily; maximum daily dose is 40 mg. GERD with or without esophagitis and ulcerations (1 year to less than 17 years): Dosing is generally similar to Peptic Ulcer Disease for this age group.

Safety & Warnings

Common Side Effects

Common side effects include headache, dizziness, constipation, and diarrhea.
Other reported adverse reactions include nausea, vomiting, excess gas, stomach ache, abdominal discomfort, anorexia, appetite loss, fatigue, rash, GI upset, liver enzyme abnormalities, angioedema, arthralgia (joint pain), muscle cramps, itchy skin, breathing difficulties, heartbeat irregularity, reversible gynecomastia (enlargement of breast tissues in males), toxic epidermal necrolysis (a rare and serious skin condition), and AV block (a type of heart block).

Serious Warnings

Black Box Warning: None
**Pregnancy & Lactation:** Use in pregnancy only if benefits outweigh risks; consultation with a doctor is advised.
Local data regarding lactation is contradictory, with one source stating contraindication and another suggesting safety with consultation.
Caution is advised.
**Underlying Conditions:** Patients with impaired renal function, liver disorders, or lupus erythematosus require careful consideration.
Malignancies, particularly gastric carcinoma, must be excluded prior to therapy due to drug sensitivity in such patients.
**Monitoring:** For prolonged therapy, regular monitoring of blood count and liver function is recommended.
**Elderly:** Elderly patients may exhibit increased susceptibility to adverse effects.
**Administration:** Tablets/capsules should be swallowed whole; do not crush, chew, or break.
Adhere strictly to prescribed dosage; do not exceed.
**Allergy & Hypersensitivity:** Inform your doctor about any known allergies, including to inactive ingredients.
Discontinue use and seek medical attention if an allergic response occurs.
**Pre-Surgical Information:** Disclose all medications (prescription, nonprescription, herbal) to your doctor or dentist before any surgical procedures.
**Bone Health:** Local data mentions that proton pump inhibitors (PPIs) may increase the risk of bone fractures with long-term, high-dose use, particularly in the elderly, and recommends calcium and vitamin D supplementation.
(Note: Famotidine is an H2-receptor antagonist, not a PPI).
**Storage:** Store at room temperature, away from direct heat and sunlight, and out of reach of children and pets.
Ensure the quality seal is intact.

How it Works (Mechanism of Action)

Famotidine is a competitive inhibitor of histamine-2 (H2) receptors. Its primary clinically important pharmacologic activity is the inhibition of gastric secretion, leading to the suppression of both acid concentration and volume of gastric secretion, with proportional changes in pepsin secretion.